Literature DB >> 22270432

Treatment of multifocal Bowen's disease in immunocompromised women with surgery and topical imiquimod.

Suhasini Kaushal1, Melissa Merideth, Pallavi Kopparthy, Tajana Klepac Pulanic, Pamela Stratton.   

Abstract

BACKGROUND: In human immunodeficiency virus (HIV)-infected women, Bowen's disease may be difficult to treat successfully with surgery alone. Imiquimod cream, effective in treating Bowen's disease in healthy women, may be a useful postsurgical treatment in immunocompromised women. CASES: Two HIV-infected women had both Bowen's disease and severe cervical dysplasia. In both cases, Bowen's disease, but not cervical dysplasia, recurred after surgical treatment. When treated with topical 5% imiquimod cream twice weekly for 4 months, 70-80% reduction in lesions were observed in both patients. Follow-up biopsies of remaining lesions were vulvar intraepithelial neoplasia 1.
CONCLUSION: Imiquimod cream, in combination with surgical treatment, may be an appropriate strategy for treatment of Bowen's disease in HIV-infected and other immunocompromised women.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22270432      PMCID: PMC3266510          DOI: 10.1097/AOG.0b013e318236f1a0

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Photodynamic therapy in combination with CO2 laser for the treatment of Bowen's disease.

Authors:  Hong Cai; Yi-xia Wang; Ji-Chun Zheng; Ping Sun; Zhi-yong Yang; Yuan-li Li; Xiao-yong Liu; Qiang Li; Wei Liu
Journal:  Lasers Med Sci       Date:  2015-04-22       Impact factor: 3.161

2.  Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.

Authors:  Elizabeth A Stier; Stephen E Goldstone; Mark H Einstein; Naomi Jay; John M Berry; Timothy Wilkin; Jeannette Y Lee; Teresa M Darragh; Maria Da Costa; Lori Panther; David Aboulafia; Joel M Palefsky
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

3.  Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Lorenzo Galluzzi; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

4.  Malignant degeneration of diffuse intertriginous flat warts in a patient with AIDS.

Authors:  Jacob W Charny; Peter L Rady; Stephen K Tyring; Carrie L Kovarik
Journal:  JAAD Case Rep       Date:  2018-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.